Vontobel Holding Ltd. Raises Stock Holdings in IQVIA Holdings Inc. $IQV

Vontobel Holding Ltd. boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 909.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 550,430 shares of the medical research company’s stock after purchasing an additional 495,884 shares during the period. Vontobel Holding Ltd. owned about 0.32% of IQVIA worth $104,549,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. OLD National Bancorp IN purchased a new position in shares of IQVIA in the 3rd quarter worth about $291,000. Farther Finance Advisors LLC boosted its stake in IQVIA by 172.1% in the third quarter. Farther Finance Advisors LLC now owns 1,083 shares of the medical research company’s stock valued at $206,000 after acquiring an additional 685 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its position in shares of IQVIA by 16.7% during the 3rd quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,756 shares of the medical research company’s stock valued at $334,000 after acquiring an additional 251 shares during the period. HBK Sorce Advisory LLC purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $214,000. Finally, Kaufman Rossin Wealth LLC bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $231,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IQV. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday. Redburn Partners set a $214.00 price objective on IQVIA in a report on Wednesday, September 3rd. Barclays set a $230.00 price objective on shares of IQVIA in a report on Monday, December 15th. Truist Financial reiterated a “buy” rating and issued a $265.00 target price (up previously from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Finally, BMO Capital Markets started coverage on shares of IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.19.

IQVIA Trading Up 0.3%

Shares of IQVIA stock opened at $225.15 on Wednesday. The company’s 50-day moving average price is $219.88 and its 200-day moving average price is $193.90. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $234.29. The company has a market cap of $38.34 billion, a price-to-earnings ratio of 30.88, a PEG ratio of 2.52 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the firm posted $2.84 EPS. IQVIA’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.